A. General Description of Advisory Firm Oppenheimer Alternative Investment Management, LLC (“OAIM”) was formed April 6, 2006. OAIM is a series limited liability company. It provides general advisory and management services to businesses and institutional clients other than investment companies, and provides portfolio management for pooled investment vehicles. A separate series of OAIM is the general partner or managing member, as the case may be (the “General Partner”) of each of the funds listed below (the “Funds”), and provides investment advisory services to the Funds with the assistance of employees of Oppenheimer Asset Management Inc. (the “Sponsor” or “OAM”). OAM is an SEC registered investment adviser. OAIM is an affiliate of OAM, wholly owned by Oppenheimer Holdings, Inc. (“OPY”), a publicly traded company listed on the New York Stock Exchange (“NYSE”). Albert G. Lowenthal Chairman of the Board and Chief Executive Officer of OPY, controls more than 50% of the voting securities of OPY. OAIM has retained Oppenheimer & Co. Inc. (“Oppenheimer”), an affiliate of OAIM, to act as administrator to the Funds. Oppenheimer may sub-delegate certain administrative functions and currently has such arrangements. The PE Funds (defined below) pay their management fees to Oppenheimer and not to OAIM. B. Description of Advisory Services OAIM provides advisory services to the following Funds: Private Equity Funds (the “PE Funds”): 1) Oppenheimer Global Resource Private Equity Fund I, L.P. (“OGR PE”): a private equity fund which invests both indirectly (through underlying private equity funds (its “OGR Underlying Funds”)) and directly in securities issued by companies that focus on Natural Resource and Related Assets. OGR PE is no longer accepting new investor commitments and or making new investments. 2) Oppenheimer Global Resource Private Equity Offshore Fund I, L.P. (“OGR PE Offshore”): an exempted limited partnership formed and registered under the laws of the Cayman Islands. OGR PE Offshore is invested only in OGR PE and is a limited partner in OGR PE. OGR PE Offshore is no longer accepting new investor commitments. 3) Private Market Opportunity - Vista Fund I, LLC Series 1, Series 1H and Series 1H-1 (“Vista I”): a private equity fund whose principal purpose of the Company is to buy, sell, hold, vote and otherwise exercise investment discretion with respect to the securities Linse Capital CP IV, LLC and related vehicles which in turn will hold securities of ChargePoint. 4) Private Market Opportunity - Vista Fund II, LLC (“Vista II”): a private equity fund whose principal purpose is to buy, sell, hold, vote and otherwise exercise investment discretion with respect to the securities Linse Capital VAL, LLC (the “Underlying Fund”) which in turn will hold securities of Valens. 5) Private Market Opportunity - Vista Fund III, LLC (“Vista III”): a private equity fund whose principal purpose is to invest

substantially all of its assets, directly or indirectly, in a ready-to-drink cocktail company that focuses on a variety of classic craft cocktails, delivered in eco-friendly, long shelf-life packaging materials (the “Business” or “Buzzbox”). 6) Private Market Opportunity – Vista Fund V, LLC (“Vista V”): a private equity fund whose principal purpose is to invest substantially all of its assets, except for those amounts the Managing Member reserves to pay for Fund expenses, directly or indirectly, in newly-issued preferred equity and warrants of Perspectum Group, Ltd., a corporation formed under the laws of England and Wales. Perspectum is a leading commercial-stage precision health company located in the United Kingdom. Perspectum was spun out of Oxford University in 2012 and has been focused on the use of its proprietary digital technologies that enable healthcare providers to provide advanced solutions using noninvasive technology that generate clear and understandable reports, aiding decision making and helping provide better care for patients (the “Business”). Its software products combine expertise in image formation, magnetic resonance (“MR”) image analysis and artificial intelligence (“AI”) to support healthcare provider diagnosis, treatment decision-making and monitoring of the progression of chronic metabolic diseases, multi-organ pathologies and cancer, and determine whether the patient is responding to therapy. As a medical services company located in the UK, Perspectum is regulated by the Medicines and Healthcare Regulatory Agency (MHRA) and the European Medicines Agency (EMA). In 2015 Perspectum received FDA clearance for their LiverMultiScan and in 2018 launched a successful pharma solutions business that takes advantage of their proprietary technology. In 2022, the United States Food and Drug Administration (“FDA”) granted 510(k) clearance to Perspectum’s CoverScan, a non- invasive advanced cloud based software suite that provides comprehensive assessments of multi organs. Perspectum’s products have the potential to transform clinical management for millions of adult and pediatric patients worldwide by enabling more cost-effective clinical care pathways that support early detection, diagnosis and prognosis, while minimizing the need for expensive, high-risk invasive diagnostic procedures and supporting the targeted use of therapeutics. The current capital raise will be largely used for marketing to hospitals and pharmaceutical companies, as well as further research and development of their precision health technology. Investors purchase limited partnership or limited liability company interests in the Funds, and investments are made the Fund level, not for individual investors in the Funds. Assets under Management As of December 31, 2023, OAIM managed $116,284,662 of client assets on a discretionary basis. This figure includes committed capital. OAIM did not manage any client assets on a non-discretionary basis.